Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/12034754251316295 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Status of temozolomide use without insurance coverage in patients with aggressive pituitary neuroendocrine tumors.
Endocr J
March 2025
Hypothalamic & Pituitary Center, Moriyama Memorial Hospital, Tokyo 134-0081, Japan.
The 2017 World Health Organization classification described aggressive pituitary neuroendocrine tumor (PitNET) as "a tumor with strong invasiveness and rapid growth, which is difficult to treat with surgery, radiation therapy, or drug therapy," which remains a challenge in the treatment of pituitary tumors. Currently, temozolomide (TMZ) is the first-line treatment for aggressive PitNET. However, it is not yet covered by insurance in Japan.
View Article and Find Full Text PDFHigh-dose oral minoxidil for the treatment of androgenetic alopecia.
Actas Dermosifiliogr
March 2025
Servicio de Dermatología, Unidad de Tricología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España; Unidad de Tricología y Trasplante Capilar, Clínica Grupo Pedro Jaén, Madrid, España.
Low-dose oral minoxidil (≤ 5 mg daily) has emerged as an effective off-label treatment for androgenetic alopecia, outperforming topical minoxidil in terms of adherence. However, the optimal dose has not yet been determined, and high doses may cause systemic adverse effects. This retrospective study of 57 patients evaluated the safety and efficacy profile of oral minoxidil at higher doses (> 5 mg).
View Article and Find Full Text PDFManagement of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies.
J Cutan Med Surg
March 2025
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Mycosis fungoides (MF) and Sézary syndrome (SS) are subtypes of cutaneous T-cell lymphoma with numerous topical and systemic therapies. Early-stage MF can be managed with topical corticosteroids, mechlorethamine, and phototherapy. However, patients are often non-responsive to topical therapies, thus requiring systemic therapies.
View Article and Find Full Text PDFTumor-specific surface marker-independent targeting of tumors through nanotechnology and bioorthogonal glycochemistry.
J Clin Invest
March 2025
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, United States of America.
Biological targeting is crucial for effective cancer treatment with reduced toxicity but is limited by the availability of tumor surface markers. To overcome this, we developed a nanoparticle-based, Tumor-specific suRfACE maRker-independent (TRACER) targeting approach. Utilizing the unique biodistribution properties of nanoparticles, we encapsulated Ac4ManNAz to selectively label tumors with azide reactive groups.
View Article and Find Full Text PDFBroad repetitive transcranial magnetic stimulation (rTMS) of the precuneus in Alzheimer's disease: A rationale and study design.
Alzheimers Dement (N Y)
March 2025
TMS Clinical and Research Program, Neuromodulation Division Semel Institute for Neuroscience and Human Behavior at UCLA Los Angeles California USA.
Introduction: Brain network dysfunction, particularly within the default mode network (DMN), is an increasingly apparent contributor to the clinical progression of Alzheimer's disease (AD). Repetitive transcranial magnetic stimulation (rTMS) can target key DMN hubs, maintain signaling function, and delay or improve clinical outcomes in AD. Here, we present the rationale and design of a study using off-the-shelf equipment and the latest clinical evidence to expand on prior rTMS work and reduce participant burden in the process.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!